Vor Biopharma Inc. - Common Stock (VOR)
1.4300
-0.1900 (-11.73%)
NASDAQ · Last Trade: Jul 1st, 10:59 PM EDT
Detailed Quote
Previous Close | 1.620 |
---|---|
Open | 1.540 |
Bid | 1.440 |
Ask | 1.450 |
Day's Range | 1.380 - 2.040 |
52 Week Range | 0.1311 - 2.040 |
Volume | 38,853,895 |
Market Cap | 95.75M |
PE Ratio (TTM) | -0.9470 |
EPS (TTM) | -1.5 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 36,010,842 |
Chart
About Vor Biopharma Inc. - Common Stock (VOR)
Vor Biopharma Inc is a biotechnology company focused on developing innovative therapies for patients with cancer. The company is pioneering a unique approach to create engineered cell therapies that harness the power of the immune system to target and destroy cancer cells more effectively. By utilizing its proprietary platform, Vor Biopharma is working to enhance the safety and efficacy of these treatments, aiming to improve outcomes for patients suffering from various malignancies. The company is dedicated to advancing its research and development efforts to bring new hope and solutions to the oncology landscape. Read More
News & Press Releases
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Directors granted Jean-Paul Kress, the Company’s Chief Executive Officer, an option to purchase 83,296,638 shares of Vor Bio’s common stock in connection with the commencement of his employment. The foregoing stock option was granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
By Vor Biopharma · Via GlobeNewswire · July 1, 2025
On Tuesday, there are stocks with unusual volume. Let's take a look.
Via Chartmill · July 1, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · June 30, 2025
Vor Biopharma gains rights to autoimmune drug telitacicept, raises capital and names a new CEO in a major strategic reset.
Via Benzinga · June 30, 2025
Unusual volume stocks are being observed in Monday's session.
Via Chartmill · June 30, 2025
Via Benzinga · June 30, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · June 30, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · June 27, 2025
Let's have a look at what is happening on the US markets on Friday. Below you can find the stocks with an unusual volume in today's session.
Via Chartmill · June 27, 2025
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Via Chartmill · June 27, 2025
Via Benzinga · June 26, 2025
Mobix Labs, Inc. (NASDAQ: MOBX) has launched an unsolicited, non-binding proposal to acquire Peraso Inc. (NASDAQ: PRSO) in a stock-for-stock deal offering Peraso shareholders a 20% premium over the company’s 30-day average share price.
Via AB Newswire · June 26, 2025
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · June 26, 2025
Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume!
Via Chartmill · June 26, 2025
Via Benzinga · June 26, 2025
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via Chartmill · June 26, 2025
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · June 26, 2025
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.
Via Benzinga · June 26, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via Chartmill · June 26, 2025
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · June 26, 2025
Via Benzinga · June 26, 2025